Urothelial carcinoma differentiates into variant histological subtypes in approximately 25% of
cases. Since every histological variant has unique characteristics, including metastatic …

Identification of reliable molecular biomarkers that can complement clinical practice
represents a fascinating challenge in any cancer field. Urothelial carcinoma is a very …

Purpose: Neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) in patients with
nonmetastatic muscle-invasive bladder cancer (MIBC) confers an absolute survival benefit …

Background Molecular subtyping of bladder cancer has revealed luminal tumors generally
have a more favourable prognosis. However, some aggressive forms of variant histology …

Bladder cancer is a heterogeneous disease including conventional urothelial carcinoma
(UC) and its histologic variants, and non-urothelial carcinoma, including squamous and …

Background In patients with muscle-invasive urothelial bladder cancer (MIBC), molecular
alterations in immunotherapy-resistant tumors found at radical cystectomy (RC) remain …

Although urothelial carcinoma (UC) has been recognised as a homogenous disease entity
until recently, it exhibits widely diverse histological variants. Recent studies have revealed …

Neoadjuvant cisplatin-based chemotherapy (NACC) followed by radical cystectomy is the
standard treatment for localized muscle-invasive bladder cancer (MIBC). Patients who …

Background Immune checkpoint blockade has made a significant impact on the clinical
outcomes of patients with metastatic urothelial carcinoma (UC). However, evidence for this …

METHODS Comprehensive searches based on the concepts of “AI” and “urothelial cancer”
were conducted in MEDLINE, EMBASE, Web of Science, and Scopus. Study selection and …